Objective: To optimize the synthetic route of lenalidomide.
目的：优化来那度胺的合成路线。
Lenalidomide is not technically a chemotherapy drug, is given orally and in certain situations can by very effective.
来那度胺，技术上来讲并非一种化疗药物，可以口服并且某些情况下非常见效。
This paper summarizes the mechanism, pharmacokinetics, clinical application, adverse reactions and drug interactions of lenalidomide.
现对其作用机制、药动学、临床应用、不良反应、药物相互作用等做一综述。
In patients receiving lenalidomide maintenance therapy, hematologic second primary malignancies occurred in 7.5% of patients compared to 3.3% in patients receiving placebo.
接受来那度胺维持治疗的患者中，有7.5%出现了血液第二原发性恶性肿瘤，而接受安慰剂的患者中有3.3%。
The expanded indication makes lenalidomide the first and only treatment to receive FDA approval for maintenance use following autologous hematopoietic stem cell transplant.
来那度胺适应症扩展后，成为FDA批准的第一个也是唯一的用于自体造血干细胞移植后维持治疗的药物。
We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
我们在此报道一个II期多中心单一研究项试验，以评价来那度胺口服单一疗法治疗复发性或难治性侵袭性NHL的安全性和有效性。
We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
我们在此报道一个II期多中心单一研究项试验，以评价来那度胺口服单一疗法治疗复发性或难治性侵袭性NHL的安全性和有效性。
应用推荐